The corporate venturing unit returned to back a $40m series C round for the retinal disease and cancer treatment developer, taking its overall funding to more than $70m.
US-based biopharmaceutical company Iconic Therapeutics completed a $40m series C round on Monday that included Lundbeckfond Ventures, the venture capital fund backed by pharmaceutical company Lundbeck.
HBM Healthcare Investments, Cormorant Asset Management, Osage University Partners, MPM Capital and H.I.G. Capital also took part in the round.
Iconic is developing therapeutics to treat retinal disease and cancer based on tissue factor biology. The capital will fund development of its lead molecule, Icon-1, for retinal diseases and to initiate clinical trials for…
